Download Mental Health Bulletin, July 2008

Lung Cancer
January 2013
This bulletin covers aspects of lung cancer and should be of interest to multidisciplinary teams
working in this area.
Sections can include:
 Combined Modality Therapies
 Drug Therapy
 Pathology, Staging, Polymorphisms & Biomarkers
 Prognosis, Survival & Risk Factors
 Radiotherapy & Imaging
 Supportive Care & Symptom Management
 Surgery
 Tobacco & Smoking
Many of the following articles are available online via the NHS Scotland Knowledge Network.
Please use the links where provided and your ATHENS password. A complete list of
available online journals and registration for ATHENS can be found at
www.knowledge.scot.nhs.uk/
If the article you require is not available via the NHS Scotland Knowledge Network and you
would like to request a print copy, please submit your request online at
www.quest.scot.nhs.uk
This bulletin contains a selection of material gathered from a search of the evidence base, and is
not intended to be comprehensive. Professional judgment should be exercised when appraising
the material. The Library takes no responsibility for the wording, content and accuracy of the
information supplied, which has been extracted in good faith from reputable sources. NHSGGC is
not responsible for the content of external internet sites.
Compiled by:
Kirsty Coltart
Subject Librarian
Beatson West of Scotland Cancer Centre
0141 301 7285, [email protected]
1
Lung Cancer, January 2013
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
General
Altwairgi, A.K., Booth, C.M., Hopman, W.M., et al. (2012). Discordance between
conclusions stated in the abstract and conclusions in the article: analysis of
published randomized controlled trials of systemic therapy in lung cancer. Journal of
Clinical Oncology 30,28:3552-3557.
Hashemi-Sadraei, N. and Pennell, N.A. (2012). Advanced non-small cell lung cancer
(NSCLC): maintenance therapy for all?. Current Treatment Options in Oncology
13,4:478-490.
Kalemkerian, G.P., Akerley, W., Bogner, P., et al. (2013). Small cell lung cancer. Journal of
the National Comprehensive Cancer Network 11,1:78-98.
NICE. Lung Cancer Pathway .December 2012
Smith, S., Fielding, S., Murchie, P., et al. (2013). Reducing the time before consulting
with symptoms of lung cancer: a randomised controlled trial in primary care. British
Journal of General Practice 63,606:47-54.
Spigel, D.R. (2012). Treatment update in small-cell lung cancer: from limited to
extensive disease. Current Treatment Options in Oncology 13,4:505-515.
Combined Modality Therapies
Fukuda, M., Nakamura, Y., Kinoshita, A., et al. (2012). Phase II study of irinotecan and
cisplatin with concurrent split-course radiotherapy in limited-disease small cell
lung cancer. Cancer Chemotherapy & Pharmacology 70,5:645-651.
Katakami, N., Tada, H., Mitsudomi, T., et al. (2012). A phase 3 study of induction
treatment with concurrent chemoradiotherapy versus chemotherapy before surgery
in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer
(WJTOG9903). Cancer 118,24:6126-6135.
Mantini, G., Valentini, V., Meduri, B., et al. (2012). Low-dose radiotherapy as a chemopotentiator of a chemotherapy regimen with pemetrexed for recurrent non-smallcell lung cancer: A prospective phase II study. Radiotherapy & Oncology 105,2:161166.
Medford-Davis, L., Decamp, M., Recht, A., et al. (2012). Surgical management of earlystage non-small cell lung carcinoma and the present and future roles of adjuvant
therapy: a review for the radiation oncologist. International journal of radiation
oncology, biology, physics 84,5:1048-1057.
Niho, S., Kubota, K., Nihei, K., et al. (2013). Dose-escalation study of thoracic
radiotherapy in combination with pemetrexed plus Cisplatin followed by
pemetrexed consolidation therapy in Japanese patients with locally advanced
nonsquamous non-small-cell lung cancer. Clinical Lung Cancer 14,1:62-69.
Socinski, M.A., Stinchcombe, T.E., Moore, D.T., et al. (2012). Incorporating bevacizumab
and erlotinib in the combined-modality treatment of stage III non-small-cell lung
cancer: results of a phase I/II trial. Journal of Clinical Oncology 30,32:3953-3959.
Tassinari, D., Scarpi, E., Sartori, S., et al. (2012). Noninferiority trials in second-line
treatments of nonsmall cell lung cancer: a systematic review of literature with
meta-analysis of phase III randomized clinical trials. American Journal of Clinical
Oncology 35,6:593-599.
2
Lung Cancer, January 2013
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
van Baardwijk, A., Reymen, B., Wanders, S., et al. (2012). Mature results of a phase II
trial on individualised accelerated radiotherapy based on normal tissue constraints
in concurrent chemo-radiation for stage III non-small cell lung cancer. European
journal of cancer 48,15:2339-2346.
Zuccato, J.A. and Ellis, P.M. (2012). Improving referral of patients for consideration of
adjuvant chemotherapy after surgical resection of lung cancer. Current Oncology
19,6:e422-7.
Drug & Targeted Therapy
Ardizzoni, A., Tiseo, M., Boni, L., et al. (2012). Pemetrexed Versus Pemetrexed and
Carboplatin As Second-Line Chemotherapy in Advanced Non-Small-Cell Lung
Cancer: Results of the GOIRC 02-2006 Randomized Phase II Study and Pooled
Analysis With the NVALT7 Trial. Journal of Clinical Oncology 30,36:4501-4507.
Bauman, J.E., Eaton, K.D., Wallace, S.G., et al. (2012). A Phase II study of pulse dose
imatinib mesylate and weekly paclitaxel in patients aged 70 and over with
advanced non-small cell lung cancer. BMC Cancer 12,449.
Bertino, E.M., Bekaii-Saab, T., Fernandez, S., et al. (2013). A phase II study of
modulated-capecitabine and docetaxel in chemonaive patients with advanced nonsmall cell lung cancer (NSCLC). Lung Cancer 79,1:27-32.
Dazzi, C., Cariello, A., Casanova, C., et al. (2013). Gemcitabine and Paclitaxel
Combination as Second-Line Chemotherapy in Patients With Small-Cell Lung
Cancer: A Phase II Study. Clinical Lung Cancer 14,1:28-33.
Des Guetz, G., Uzzan, B., Nicolas, P., et al. (2012). Comparison of the efficacy and
safety of single-agent and doublet chemotherapy in advanced non-small cell lung
cancer in the elderly: a meta-analysis. Critical Reviews in Oncology-Hematology
84,3:340-349.
Di Maio, M., Leighl, N.B., Gallo, C., et al. (2012). Quality of life analysis of TORCH, a
randomized trial testing first-line erlotinib followed by second-line
cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer.
Journal of Thoracic Oncology: Official Publication of the International Association for the
Study of Lung Cancer 7,12:1830-1844.
Fruh, M., Cathomas, R., Siano, M., et al. (2013). Carboplatin and Paclitaxel Plus ASA404
as First-Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A
Multicenter Single Arm Phase II Trial (SAKK 15/08). Clinical Lung Cancer 14,1:34-39.
Gridelli, C., de Marinis, F., Pujol, J.L., et al. (2012). Safety, resource use, and quality of
life in paramount: a phase III study of maintenance pemetrexed versus placebo
after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell
lung cancer. Journal of Thoracic Oncology: Official Publication of the International
Association for the Study of Lung Cancer 7,11:1713-1721.
Hall, R.D., Gray, J.E. and Chiappori, A.A. (2013). Beyond the standard of care: a review
of novel immunotherapy trials for the treatment of lung cancer. Cancer Control
20,1:22-31.
Han, J.Y., Kim, H.Y., Lim, K.Y., et al. (2013). A phase II study of sunitinib in patients
with relapsed or refractory small cell lung cancer. Lung Cancer 79,2:137-142.
Han, J.Y., Nam, B.H., Kim, H.Y., et al. (2012). A randomized phase II study of
irinotecan plus cisplatin versus irinotecan plus capecitabine with or without
isosorbide-5-mononitrate in advanced non-small-cell lung cancer. Annals of Oncology
23,11:2925-2930.
3
Lung Cancer, January 2013
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
Janku, F., Berry, D.A., Gong, J., et al. (2012). Outcomes of phase II clinical trials with
single-agent therapies in advanced/metastatic non-small cell lung cancer published
between 2000 and 2009. Clinical Cancer Research 18,22:6356-6363.
Janne, P.A., Shaw, A.T., Pereira, J.R., et al. (2013). Selumetinib plus docetaxel for
KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre,
placebo-controlled, phase 2 study. Lancet Oncology 14,1:38-47.
Kitamura, K., Kubota, K., Ando, M., et al. (2013). Bevacizumab plus chemotherapy for
advanced non-squamous non-small-cell lung cancer with malignant pleural
effusion. Cancer Chemotherapy & Pharmacology 71,2:457-461.
Lee, K.H., Lee, K.Y., Jeon, Y.J., et al. (2012). Gefitinib in Selected Patients with PreTreated Non-Small-Cell Lung Cancer: Results from a Phase IV, Multicenter, NonRandomized Study (SELINE). Tuberculosis & Respiratory Diseases 73,6:303-311.
Lee, S.M., Khan, I., Upadhyay, S., et al. (2012). First-line erlotinib in patients with
advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a
double-blind, placebo-controlled, phase 3 trial. Lancet Oncology 13,11:1161-1170.
Minami, S., Kijima, T., Shiroyama, T., et al. (2013). Randomized Phase II trial of
paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy
versus gemcitabine and carboplatin followed by gemcitabine continuationmaintenance therapy in previously untreated advanced non-small cell lung cancer.
BMC Research Notes 6,3.
Mubarak, N., Gaafar, R., Shehata, S., et al. (2012). A randomized, phase 2 study
comparing pemetrexed plus best supportive care versus best supportive care as
maintenance therapy after first-line treatment with pemetrexed and cisplatin for
advanced, non-squamous, non-small cell lung cancer. BMC Cancer 12,423.
Oshita, F., Sugiura, M., Murakami, S., et al. (2013). Phase II study of nedaplatin and
irinotecan in patients with extensive small-cell lung cancer. Cancer Chemotherapy &
Pharmacology 71,2:345-350.
Petrelli, F., Borgonovo, K., Cabiddu, M., et al. (2012). Biological agents alone or in
combination as second-line therapy in advanced non-small-cell lung cancer:
systematic review of randomized studies. Expert Review of Anticancer Therapy
12,10:1299-1312.
Reck, M., Bondarenko, I., Luft, A., et al. (2013). Ipilimumab in combination with
paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung
cancer: results from a randomized, double-blind, multicenter phase 2 trial. Annals of
Oncology 24,1:75-83.
Rong, B., Yang, S., Li, W., et al. (2012). Systematic review and meta-analysis of
Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone
for treating advanced non-small cell lung cancer. World Journal of Surgical Oncology
10,170.
Shiroyama, T., Kijima, T., Komuta, K., et al. (2012). Phase II tailored S-1 regimen study
of first-line chemotherapy in elderly patients with advanced and recurrent nonsmall cell lung cancer. Cancer Chemotherapy & Pharmacology 70,6:783-789.
Sodja, E., Knez, L., Kern, I., et al. (2012). Impact of ERCC1 expression on treatment
outcome in small-cell lung cancer patients treated with platinum-based
chemotherapy. European journal of cancer 48,18:3378-3385.
Stathopoulos, G.P., Trafalis, D., Dimitroulis, J., et al. (2013). Combination of three
cytotoxic agents in small-cell lung cancer. Cancer Chemotherapy & Pharmacology
71,2:413-418.
4
Lung Cancer, January 2013
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
Stevenson, J.P., Langer, C.J., Somer, R.A., et al. (2012). Phase 2 trial of maintenance
bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in
advanced, nonsquamous nonsmall cell lung cancer. Cancer 118,22:5580-5587.
Sun, J.M., Lee, K.H., Kim, S.W., et al. (2012). Gefitinib versus pemetrexed as secondline treatment in patients with nonsmall cell lung cancer previously treated with
platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial. Cancer
118,24:6234-6242.
Wang, Y., Deng, G., Liu, X., et al. (2013). Monoclonal antibodies in lung cancer. Expert
Opinion on Biological Therapy 13,2:209-226.
Xiao, Y.Y., Zhan, P., Yuan, D.M., et al. (2013). Chemotherapy plus Vandetanib or
Chemotherapy Alone in Advanced Non-small Cell Lung Cancer: A Meta-analysis of
Four Randomised Controlled Trials. Clinical Oncology (Royal College of Radiologists)
25,1:e7-e15.
Xiao, Y.Y., Zhan, P., Yuan, D.M., et al. (2013). Chemotherapy plus multitargeted
antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced
NSCLC: a meta-analysis of randomized controlled trials. European journal of clinical
pharmacology 69,2:151-159.
Zappa F. Droege C. Betticher D. von Moos R. Bubendorf L. Ochsenbein A. Gautschi O.
Oppliger Leibundgut E. Froesch P. Stahel R. Hess T. Rauch D. Schmid P. Mayer M. Crowe S.
Brauchli P. Ribi K. Pless M. Swiss Group for Clinical Cancer Research (SAKK). (2012).
Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous nonsmall-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based
chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK
19/05). Lung Cancer 78,3:239-244.
Zhan, J., Han, Q. and Wang, K. (2013). Development of antibody therapeutics for small
cell lung cancer. Expert opinion on investigational drugs 22,2:235-244.
Pathology, Staging, Polymorphisms & Biomarkers
Cardarella, S., Ortiz, T.M., Joshi, V.A., et al. (2012). The introduction of systematic
genomic testing for patients with non-small-cell lung cancer. Journal of Thoracic
Oncology: Official Publication of the International Association for the Study of Lung Cancer
7,12:1767-1774.
Lovly, C.M. and Horn, L. (2012). Strategies for overcoming EGFR resistance in the
treatment of advanced-stage NSCLC. Current Treatment Options in Oncology 13,4:516526.
Schildhaus, H.U., Heukamp, L.C., Merkelbach-Bruse, S., et al. (2012). Definition of a
fluorescence in-situ hybridization score identifies high- and low-level FGFR1
amplification types in squamous cell lung cancer. Modern Pathology 25,11:1473-1480.
Schnabel, P.A., Smit, E., Carpeno Jde, C., et al. (2012). Influence of histology and
biomarkers on first-line treatment of advanced non-small cell lung cancer in routine
care setting: baseline results of an observational study (FRAME). Lung Cancer
78,3:263-269.
Zimling, Z.G., Sorensen, J.B., Gerds, T.A., et al. (2012). A biomarker profile for
predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural
mesothelioma. Cancer Chemotherapy & Pharmacology 70,5:743-754.
5
Lung Cancer, January 2013
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
Prognosis, Survival & Risk Factors
Blayney, J.K., Ceresoli, G.L., Castagneto, B., et al. (2012). Response to chemotherapy is
predictive in relation to longer overall survival in an individual patient combinedanalysis with pleural mesothelioma. European journal of cancer 48,16:2983-2992.
Cortes-Jofre, M., Rueda, J.R., Corsini-Munoz, G., et al. (2012). Drugs for preventing lung
cancer in healthy people. Cochrane Database of Systematic Reviews 10,002141.
Hotta, K., Suzuki, E., Di Maio, M., et al. (2013). Progression-free survival and overall
survival in phase III trials of molecular-targeted agents in advanced non-small-cell
lung cancer. Lung Cancer 79,1:20-26.
Irwin, K.E., Greer, J.A., Khatib, J., et al. (2013). Early palliative care and metastatic
non-small cell lung cancer: Potential mechanisms of prolonged survival. Chronic
Respiratory Disease 10,1:35-47.
Ochi, N., Hotta, K., Takigawa, N., et al. (2012). Treatment-related death in patients
with small-cell lung cancer in phase III trials over the last two decades. PLoS ONE
[Electronic Resource] 7,8:e42798.
Reck, M., Thatcher, N., Smit, E.F., et al. (2012). Baseline quality of life and performance
status as prognostic factors in patients with extensive-stage disease small cell lung
cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
Lung Cancer 78,3:276-281.
Radiotherapy & Imaging
Alderliesten, T., Sonke, J.J., Betgen, A., et al. (2012). 3D surface imaging for monitoring
intrafraction motion in frameless stereotactic body radiotherapy of lung cancer.
Radiotherapy & Oncology 105,2:155-160.
Behrendt, F.F., Temur, Y., Verburg, F.A., et al. (2012). PET/CT in lung cancer: Influence
of contrast medium on quantitative and clinical assessment. European radiology
22,11:2458-2464.
Ge, H., Cai, J., Kelsey, C.R., et al. (2013). Quantification and Minimization of
Uncertainties ofInternal Target Volume for Stereotactic Body Radiation Therapy of
Lung Cancer. International journal of radiation oncology, biology, physics 85,2:438-443.
Koay, E.J., Lege, D., Mohan, R., et al. (2012). Adaptive/nonadaptive proton radiation
planning and outcomes in a phase II trial for locally advanced non-small cell lung
cancer. International journal of radiation oncology, biology, physics 84,5:1093-1100.
Lin, Y.Y., Chen, J.H., Ding, H.J., et al. (2012). Potential value of dual-time-point 18FFDG PET compared with initial single-time-point imaging in differentiating
malignant from benign pulmonary nodules: a systematic review and meta-analysis.
Nuclear medicine communications 33,10:1011-1018.
Pallin, M., Walsh, S., O'Driscoll, M.F., et al. (2012). Overwhelming support among urban
Irish COPD patients for lung cancer screening by low-dose CT scan. Lung 190,6:621628.
Reveiz, L., Rueda, J.R. and Cardona, A.F. (2012). Palliative endobronchial
brachytherapy for non-small cell lung cancer. Cochrane Database of Systematic Reviews
12,004284.
6
Lung Cancer, January 2013
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
Robinson, C.G., Dewees, T.A., El Naqa, I.M., et al. (2013). Patterns of failure after
stereotactic body radiation therapy or lobar resection for clinical stage I non-smallcell lung cancer. Journal of Thoracic Oncology: Official Publication of the International
Association for the Study of Lung Cancer 8,2:192-201.
Sharples, L.D., Jackson, C., Wheaton, E., et al. (2012). Clinical effectiveness and costeffectiveness of endobronchial and endoscopic ultrasound relative to surgical
staging in potentially resectable lung cancer: results from the ASTER randomised
controlled trial. Health technology assessment (Winchester, England) 16,18:1-75.
Shirvani, S.M., Jiang, J., Chang, J.Y., et al. (2012). Comparative effectiveness of 5
treatment strategies for early-stage non-small cell lung cancer in the elderly.
International journal of radiation oncology, biology, physics 84,5:1060-1070.
Shultz, D.B., Grecula, J.C., Hayman, J., et al. (2013). The optimal use of radiotherapy in
small cell lung cancer. Journal of the National Comprehensive Cancer Network 11,1:107114.
Siva, S., Shaw, M., Chesson, B., et al. (2012). Analysis of the impact of chest wall
constraints on eligibility for a randomized trial of stereotactic body radiotherapy of
peripheral stage I non-small cell lung cancer. Journal of Medical Imaging & Radiation
Oncology 56,6:654-660.
Udrescu, C., Mornex, F., Tanguy, R., et al. (2013). ExacTrac Snap Verification: A New
Tool for Ensuring Quality Control for Lung Stereotactic Body Radiation Therapy.
International journal of radiation oncology, biology, physics 85,1:e89-94.
van Baardwijk, A., Tome, W.A., van Elmpt, W., et al. (2012). Is high-dose stereotactic
body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC) overkill?
A systematic review. Radiotherapy & Oncology 105,2:145-149.
Wu, G., Lian, J. and Shen, D. (2012). Improving image-guided radiation therapy of
lung cancer by reconstructing 4D-CT from a single free-breathing 3D-CT on the
treatment day. Medical physics 39,12:7694-7709.
Wu, L.M., Xu, J.R., Gu, H.Y., et al. (2012). Preoperative mediastinal and hilar nodal
staging with diffusion-weighted magnetic resonance imaging and
fluorodeoxyglucose positron emission tomography/computed tomography in
patients with non-small-cell lung cancer: which is better?. Journal of Surgical
Research 178,1:304-314.
Zhang, X.J., Sun, J.G., Sun, J., et al. (2012). Prediction of radiation pneumonitis in lung
cancer patients: a systematic review. Journal of Cancer Research & Clinical Oncology
138,12:2103-2116.
Zhao, B., Yang, Y., Li, T., et al. (2012). Dosimetric effect of intrafraction tumor motion
in phase gated lung stereotactic body radiotherapy. Medical physics 39,11:6629-6637.
Supportive Care & Symptom Management
Bagan, P., Berna, P., De Dominicis, F., et al. (2013). Nutritional status and postoperative
outcome after pneumonectomy for lung cancer. Annals of Thoracic Surgery 95,2:392396.
Chambers, S.K., Dunn, J., Occhipinti, S., et al. (2012). A systematic review of the impact
of stigma and nihilism on lung cancer outcomes. BMC Cancer 12,184.
Dhillon, H.M., van der Ploeg, H.P., Bell, M.L., et al. (2012). The impact of physical activity
on fatigue and quality of life in lung cancer patients: a randomised controlled trial
protocol. BMC Cancer 12,572.
7
Lung Cancer, January 2013
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
Hirsh, V., Cadranel, J., Cong, X.J., et al. (2013). Symptom and Quality of Life Benefit of
Afatinib in Advanced Non-Small-Cell Lung Cancer Patients Previously Treated with
Erlotinib or Gefitinib: Results of a Randomized Phase IIb/III Trial (LUX-Lung 1).
Journal of Thoracic Oncology: Official Publication of the International Association for the
Study of Lung Cancer 8,2:229-237.
Hollen, P.J., Gralla, R.J., Stewart, J.A., et al. (2013). Can a computerized format replace
a paper form in PRO and HRQL evaluation? Psychometric testing of the computerassisted LCSS instrument (eLCSS-QL). Supportive Care in Cancer 21,1:165-172.
Hwang, C.L., Yu, C.J., Shih, J.Y., et al. (2012). Effects of exercise training on exercise
capacity in patients with non-small cell lung cancer receiving targeted therapy.
Supportive Care in Cancer 20,12:3169-3177.
Krebber, A.M., Leemans, C.R., de Bree, R., et al. (2012). Stepped care targeting
psychological distress in head and neck and lung cancer patients: a randomized
clinical trial. BMC Cancer 12,173.
Morano, M.T., Araujo, A.S., Nascimento, F.B., et al. (2013). Preoperative pulmonary
rehabilitation versus chest physical therapy in patients undergoing lung cancer
resection: a pilot randomized controlled trial. Archives of Physical Medicine &
Rehabilitation 94,1:53-58.
Nicklasson, M., Elfstrom, M.L., Olofson, J., et al. (2013). The impact of individual quality
of life assessment on psychosocial attention in patients with chest malignancies: a
randomized study. Supportive Care in Cancer 21,1:87-95.
Nwosu, A.C., Bayly, J.L., Gaunt, K.E., et al. (2012). Lung cancer and rehabilitation-what are the barriers? Results of a questionnaire survey and the development of
regional lung cancer rehabilitation standards and guidelines. Supportive Care in
Cancer 20,12:3247-3254.
Palma, D.A., Senan, S., Tsujino, K., et al. (2013). Predicting Radiation Pneumonitis
After Chemoradiation Therapy for Lung Cancer: An International Individual Patient
Data Meta-analysis. International journal of radiation oncology, biology, physics 85,2:444450.
Pardon, K., Deschepper, R., Vander Stichele, R., et al. (2012). Changing preferences for
information and participation in the last phase of life: a longitudinal study among
newly diagnosed advanced lung cancer patients. Supportive Care in Cancer
20,10:2473-2482.
Rowlands, S. and Callen, J. (2013). A qualitative analysis of communication between
members of a hospital-based multidisciplinary lung cancer team. European Journal of
Cancer Care 22,1:20-31.
Saad, E.D., Adamowicz, K., Katz, A., et al. (2012). Assessment of quality of life in
advanced non-small-cell lung cancer: an overview of recent randomized trials.
Cancer treatment reviews 38,6:807-814.
Stigt, J.A., Uil, S.M., van Riesen, S.J., et al. (2013). A randomized controlled trial of
postthoracotomy pulmonary rehabilitation in patients with resectable lung cancer.
Journal of Thoracic Oncology: Official Publication of the International Association for the
Study of Lung Cancer 8,2:214-221.
Vogelius, I.R. and Bentzen, S.M. (2012). A literature-based meta-analysis of clinical
risk factors for development of radiation induced pneumonitis. Acta Oncologica
51,8:975-983.
Walker, J., Sawhney, A., Hansen, C.H., et al. (2013). Treatment of depression in people
with lung cancer: A systematic review. Lung Cancer 79,1:46-53.
8
Lung Cancer, January 2013
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
Surgery
Cheng, Y.D., Duan, C.J., Dong, S., et al. (2012). Clinical controlled comparison between
lobectomy and segmental resection for patients over 70 years of age with clinical
stage I non-small cell lung cancer. European Journal of Surgical Oncology 38,12:11491155.
Donington, J., Ferguson, M., Mazzone, P., et al. (2012). American College of Chest
Physicians and Society of Thoracic Surgeons Consensus Statement for Evaluation
and Management for High-Risk Patients With Stage I Non-small Cell Lung Cancer.
Chest 142,6:1620-1635.
Tobacco and Smoking
Bize, R., Burnand, B., Mueller, Y., et al. (2012). Biomedical risk assessment as an aid for
smoking cessation. Cochrane Database of Systematic Reviews 12,004705.
Poghosyan, H., Kennedy Sheldon, L. and Cooley, M.E. (2012). The impact of computed
tomography screening for lung cancer on smoking behaviors: a teachable moment?.
Cancer nursing 35,6:446-475.
Please note that the journal articles you are accessing are subject to the terms and conditions
imposed by the publisher, so there will be a limit on the number of articles an individual may
download or print from a single issue of a journal. You can consult your local NHSGGC library with
any queries.
If you have any questions regarding this or any other library services please contact Library staff –
contact details are at the beginning of the bulletin.
Sources used for this bulletin:
OVID databases
9
Lung Cancer, January 2013
Kirsty Coltart, Subject Librarian, NHSGGC Library Network